Incidence of Side Effects During Tenofovir Alafenamide Monotherapy in Patients with Chronic Hepatitis B
Journal Title: Diseases & Research - Year 2023, Vol 3, Issue 1
Abstract
Objective Tenofovir alafenamide (TAF) is a new prodrug of tenofovir that is widely used in chronic hepatitis B (CHB) patients, and its side effects have rarely been reported. We aimed to evaluate the incidence of side effects of TAF in CHB patients. Methods We conducted a cross-sectional study that enrolled CHB patients who initiated TAF treatment at West China Hospital from January 2018 to January 2021, and investigated the incidence of side effects by questionnaire. The questionnaire included basic patient characteristics, symptoms, the time of side effects, etc. Results A total of 256 eligible patients with a median age of 39 (33, 47) years participated in this study. After 94 (65, 131.5) weeks of TAF treatment, 32% (82/256) of patients experienced side effects, some patients experienced multiple symptoms. The time to side effects was 4 (1, 12) weeks and the degree was mild, the occurrence of side effects had no significant effect on antiviral efficacy (P > 0.05). The incidence of skin system side effects was the highest, accounting for 29.3% (75/256) of patients, with alopecia (21.1%) as the main symptom. Systemic and musculoskeletal adverse effects occurred in 27% (69/256) of patients. Gastrointestinal side effects accounted for 18.8% (48/256) of patients, and the main symptom was abdominal distension (12.1%). In addition, 9% (23/256) of patients experienced neurological side effects, 8.6% (22/256) of patients experienced laboratory abnormalities, and 4% (10/256) of patients experienced bone impairment. Conclusion CHB patients treated with TAF had a higher incidence of side effects. Fortunately, these side effects were mild and did not affect the antiviral efficacy.
Authors and Affiliations
Fada Wang, Jing Zhou, Lanqing Li, Yujing Li, Yongfang Liu, Enqiang Chen
Keywords
Related Articles
- EP ID EP740140
- DOI 10.54457/DR.202301004
- Views 45
- Downloads 0
Recurrent Middle Ear Cancer: Case Report
Background: Middle ear cancer is clinically uncommon, representing approximately 1.5% of ear malignancies and 0.03% to 0.06% of all cancers. Recurrent cases of middle ear cancer are particularly rare. This report discuss...
Secretome of Dental Pulp-Derived Stem Cells Reduces Inflammation and Proliferation of Glioblastoma Cells by Deactivating Mapk-Akt Pathway
Background Dental pulp-derived stem cells (DPSC) is a promising therapy as they modulate the immune response, so we evaluated the inhibitory effect of DPSC secretome (DPSC℗) on the proliferation and inflammation in human...
Significance of Liquid Biopsy Containing Circulating Tumor DNA (ctDNA) Analysis for Evaluation and Management of Metastatic Cancer
According to the GLOBOCAN 2020 data from WHO, nearly 10 million deaths took place due to cancer thus, cancer became a leading cause of death all over the world. The most common cancer are breast cancer, lung cancer, colo...
ransient Hypopituitarism in a Patient Developing Diabetic Ketoacidosis after COVID-19: Case Report
Since the beginning of the novel coronavirus disease (COVID-19) pandemic, many papers have been published about the association between COVID-19 and various endocrine abnormalities. Accumulated data so far reveal that hy...
Salvage Therapy with Gilteritinib Plus Venetoclax for FLT3-ITD-Positive AML: A Case Report and Literature Review
FMS-like tyrosine kinase 3 (FLT3) mutations occur in around 30% of patients in acute myeloid leukemia (AML), and are generally associated with unfavorable outcomes. Gilteritinib is a highly specific second-generation cla...